about
Agomelatine versus other antidepressive agents for major depressionMethylphenidate use in pregnancy and lactation: a systematic review of evidenceAddiction.Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD studyA discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data.Response to Damkier.Benzodiazepines: risks and benefits. A reconsideration.Antidepressant-induced jitteriness/anxiety syndrome: systematic review.Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis.The impact of aging, cognition, and symptoms on functional competence in individuals with schizophrenia across the lifespan.Symptoms of generalized anxiety disorder but not panic disorder at age 15 years increase the risk of depression at 18 years in the Avon Longitudinal Study of Parents and Children (ALSPAC) cohort study.Emotional symptoms in children: The effect of maternal depression, life events, and COMT genotype.Anxiety--bridging the heart/mind divide.Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.Anxiety and cardiovascular disease.Treatment: special conditions. Psychological aspects relating to the treatment of hypertension.Evidence for serotonin function as a neurochemical difference between fear and anxiety disorders in humans?The Impact of Sertraline Co-Administration on the Pharmacokinetics of Olanzapine: A Population Pharmacokinetic Analysis of the STOP-PD.Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine.Mirtazapine added to selective serotonin reuptake inhibitors for treatment-resistant depression in primary care (MIR trial): study protocol for a randomised controlled trial.Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.Potential for Drug-Drug Interactions with Adjunctive Tramadol Use in Treatment of Obsessive-Compulsive Disorder.Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries.Severe laryngeal dystonia in a patient receiving zuclopenthixol "Acuphase" and fluoxetine.Effects of acute tryptophan depletion in serotonin reuptake inhibitor-remitted patients with generalized anxiety disorder.Drug-drug interactions in general hospital and psychiatric hospital in-patients prescribed psychotropic medications.Panic disorder and subthreshold panic in the UK general population: epidemiology, comorbidity and functional limitation.Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: an [11C]diprenorphine PET study.Varenicline for smoking cessation: a placebo-controlled, randomized study.Cardiac slowing and acute tryptophan depletion: a comment on the paper by van der Veen et al.Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants.SSRI-antipsychotic combination in psychotic depression: sertraline pharmacokinetics in the presence of olanzapine, a brief report from the STOP-PD study.Panic and hypertension: brothers in arms through 5-HT?Manifesto for a European anxiety disorders research network.Individual oral symptoms in burning mouth syndrome may be associated differentially with depression and anxiety.A U-shaped relationship between systolic blood pressure and panic symptoms: the HUNT study.Association of panic disorder and panic attacks with hypertension.PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions.Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.No Evidence That Panic Attacks Are Associated With the White Coat Effect in Hypertension
P50
Q24201746-F39C6CB4-4781-46D0-8B14-FE4DA47F0BAAQ26851791-D9113503-93B6-48FD-BB47-517EBAF2CEE1Q33186725-B0CCC2FB-0FEC-4FDD-A241-F2EBFC4E99A1Q33835886-A2277FD5-8A8E-4B79-A431-78A6E2CB6679Q33858665-069BD51C-26B8-4BC3-9029-E4D3A1E0FB34Q33888029-8F35EF8F-1757-4211-8878-F5C5B93C499EQ34373385-22B89C8C-4BFD-4329-B05C-F0EBC5075377Q34608307-EAFE9BAE-1B96-4D19-B65D-EB34EE88166FQ34617901-FEFF236A-ACB8-4D3F-8B10-E6E0F5B954BFQ35096578-B2A03166-896F-4CFD-85F8-7BE4DCE12E5AQ36951052-98C9BF4D-BEBF-4BE3-943D-594054470649Q37351544-261404A5-5C17-4C83-B2A3-88F95385E6DFQ37433307-B72F71A7-C0BE-4583-A7B1-6A186E534D3FQ37686937-3D7C8CC2-909B-4942-829F-D5AD54E51B26Q38250008-8760911B-20D2-45B4-89CE-376B0D5BDDA3Q38351428-94508038-449D-4FA1-8C86-D8D9F5269607Q38983506-7C6483F0-7A20-4F45-BCF9-328A52B57E83Q40943084-B64C5BB4-7D68-4030-AF2C-1A33445316DAQ41093298-0849118C-AD8B-4798-A171-1227B5EBEB29Q41117480-3A3C69D3-1FAB-4080-85CB-149401A051FCQ42601536-DBBF828B-77EA-416F-8AE8-78B8AC41CB77Q42867545-3B1A177A-1D3F-4EA6-A981-517841D95A31Q42953739-98DDCE52-99E9-410E-91E3-51D692D47506Q43154119-BEE88501-9F81-411F-8F4B-7AC5B3736EBAQ43236150-ABDBE373-1182-4441-A686-B3F083B15AE7Q43727588-5FB45C3F-D3CE-493E-9B07-BBC53E264C39Q43978388-855B536A-FACB-4B9D-A531-C1C14EB04359Q44343376-1391E3DC-AB0F-4991-BCC5-70F087E3FA98Q46134090-6ADC97F4-BB16-49B3-9158-E15F194537F6Q46198092-E9992005-4586-4A14-91ED-227AB86480B0Q46329263-97BCF7D1-B6A0-4CFF-8658-2DF7549B95C4Q46466970-590B63C0-2E30-4ACF-AD37-C9980D3DD1FEQ46977405-83EA10F9-05EB-4A2B-BE5C-6E076EEC00AFQ47398843-E32E9E53-B765-4DDB-AB88-68CD795A6FE4Q47629185-9C3E1C42-9690-4417-B313-EE049D3C8CCCQ48753281-E74A9CA0-712D-4EE0-A53C-229B835AE44AQ51085164-BE30118B-05AA-4140-8C56-E652AFEE2941Q51906451-8D91E3D3-AFAA-4B01-A8AF-F3B79995CC88Q53091817-6FAF9FD4-1951-4529-8149-7D259432419FQ57313442-B8A4415E-400A-4693-990E-720ECC458B50
P50
description
researcher ORCID ID = 0000-0003-0095-5993
@en
wetenschapper
@nl
name
Simon J.C. Davies
@ast
Simon J.C. Davies
@en
Simon J.C. Davies
@es
Simon J.C. Davies
@nl
type
label
Simon J.C. Davies
@ast
Simon J.C. Davies
@en
Simon J.C. Davies
@es
Simon J.C. Davies
@nl
prefLabel
Simon J.C. Davies
@ast
Simon J.C. Davies
@en
Simon J.C. Davies
@es
Simon J.C. Davies
@nl
P106
P1153
35465189400
P21
P214
109149233542776511233
P31
P496
0000-0003-0095-5993
P7859
viaf-109149233542776511233